- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01267955
Vismodegib in Treating Patients With Advanced Chondrosarcomas
A Phase 2 Study of GDC-0449 in Patients With Advanced Chondrosarcomas
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To evaluate the antitumor activity of GDC-0449 (vismodegib) in terms of 6-month clinical benefit rate (complete response, partial response, and stable disease, as per the revised Response Evaluation Criteria in Solid Tumors [RECIST] criteria 2009).
SECONDARY OBJECTIVES:
I. Best overall response (as per the revised RECIST criteria 2009). II. 1- and 2-year progression-free survival. III. 1- and 2-year overall survival. IV. GDC-0449 safety. V. Pharmacogenomics analysis of predictive markers of treatment outcome.
OUTLINE:
Patients receive vismodegib orally (PO) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up every 3 months.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Bordeaux, France, 33076
- Institut Bergonie Cancer Center
-
Lille, France, 59020
- Centre Oscar Lambert
-
Lyon, France, 69373
- Centre Léon Bérard
-
Marseille, France, 13385
- Hôpital de la Timone
-
Paris, France, 75005
- Institut Curie Paris
-
Villejuif, France, 94805
- Gustave Roussy
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients must have histologically confirmed diagnosis of chondrosarcoma (conventional, mesenchymal, dedifferentiated or clear cell subtypes)
- Patients must have measurable disease (outside any previously irradiated field) defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 10 mm with spiral computed tomography (CT) scan
- No more than three prior lines of chemotherapy for advanced disease (including no more than 450 mg/m^2 doxorubicin); at least three weeks since last chemotherapy (six weeks in case of nitrosoureas and mitomycin C), immunotherapy or any other pharmacological treatment and/or radiotherapy
- Life expectancy of greater than 3 months
- Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)
- Leukocytes >= 3,000/mcL
- Absolute neutrophil count >= 1,500/mcL
- Platelets >= 100,000/mcL
- Total bilirubin within normal institutional limits
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal
- Creatinine within normal institutional limits OR creatinine clearance > 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal
- Metastatic or unresectable locally advanced disease
- Documented disease progression (as per RECIST) before study entry
- Women of child-bearing potential and men must use two forms of contraception (i.e., barrier contraception and one other method of contraception) at least 4 weeks prior to study entry, for the duration of study participation, and for at least 24 months post-treatment for female patients and for 2 months for male patients; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
Women of childbearing potential are required to have a negative serum pregnancy test (with a sensitivity of at least 25 mIU/mL) within 7 days prior to initiation of GDC-0449 (serum or urine); a pregnancy test (serum or urine) will be administered every 4 weeks while on study within the 24-hour period prior to the administration of GDC-0449; a positive urine test must be confirmed by a serum pregnancy test; prior to dispensing GDC-0449, the investigator must confirm and document the patient's use of two contraceptive methods, dates of negative pregnancy test, and confirm the patient's understanding of the teratogenic potential of GDC-0449
Women of childbearing potential are defined as follows:
- Patients with regular menses
- Patients with amenorrhea, irregular cycles, or using a contraceptive method that precludes withdrawal bleeding
- Women who have had a tubal ligation
Women are considered not to be of childbearing potential for the following reasons:
- The patient has undergone hysterectomy and/or bilateral oophorectomy
- The patient is post-menopausal defined by amenorrhea for at least 1 year in a woman > 50 years old
- The patient has permanent premature ovarian failure confirmed by specialist gynecologist
- Ability to understand and the willingness to sign a written informed consent document
- In accordance with French Regulatory Authorities: Patients with French Social Security in compliance with the French law relating to biomedical research (Huriet Law 88-1138 and related decrees)
Exclusion Criteria:
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 3 weeks earlier
- Patients may not be receiving any other investigational agents
- Patients with known brain metastases should be excluded from this clinical trial
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to GDC-0449 or other agents used in the study
- Patients with malabsorption syndrome or other condition that would interfere with intestinal absorption; patients must be able to swallow capsules
- Patients with clinically important history of liver disease, including viral or other hepatitis, or cirrhosis are ineligible
- Patients with uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation, are excluded from this study
- Tumor tissue sample not available for pathological review and/or correlative studies
- Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with GDC-0449; these potential risks may also apply to other agents used in this study
- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral therapy are ineligible
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (vismodegib)
Patients receive vismodegib PO on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Correlative studies
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Benefit Rate (CBR) Based on Centralized Imaging Review as Per RECIST 1.1
Time Frame: At 6 months after inclusion
|
CBR was defined as the percentage of participants with complete or partial responses (CR, PR) or stable disease (SD) per RECIST 1.1.
CR was defined as disappearance of all non-nodal target lesions.
PR was defined as at least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.
Analysis of response was performed based on radiological centralized review.
A 2-stage optimal Simon's design with 37 participants (first stage: 17 participants) was used.
If 3 or less non-progressions (CR + PR + SD) at 6 months were observed during stage 1 (out of 17 participants), the trial would stopped early.
Otherwise, 20 additional patients would be accrued for stage 2. If 11 or more non-progressions (out of 37 participants) were observed at the end of recruitment, further investigation of this therapy would be warranted.
|
At 6 months after inclusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free Survival
Time Frame: Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 3 years
|
Will be analyzed using the Kaplan-Meier method.
The median survival rates will be reported with a 95% confidence interval.
Median follow-up will be calculated using the reverse Kaplan-Meier method.
|
Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 3 years
|
Overall Survival Per Response Evaluation Criteria in Solid Tumors Criteria 2009
Time Frame: Time from start of treatment to the time of death, assessed up to 3 years
|
Overall survival will be analyzed using the Kaplan-Meier method.
The median survival rates will be reported with a 95% confidence interval.
Median follow-up will be calculated using the reverse Kaplan-Meier method.
|
Time from start of treatment to the time of death, assessed up to 3 years
|
Duration of Response
Time Frame: From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Will be described in responding subjects using descriptive statistics (median, extreme values, etc.).
|
From the time measurement criteria are met for complete response or partial response (whichever is first recorded) until the first date that recurrent or progressive disease is objectively documented, assessed up to 3 years
|
Mutational Status of Patched 1 and Smoothened
Time Frame: Baseline
|
The 6-months clinical benefit rate will be correlated with the mutational status of patched and smoothened in order to identify predictive factors of clinical benefit from vismodegib.
|
Baseline
|
Expression Pattern of Hedgehog Signaling Molecules by Using Quantitative Reverse Transcription-polymerase Chain Reaction and Immunohistochemistry
Time Frame: Baseline
|
The 6-months clinical benefit rate will be correlated with the expression score of hedgehog signaling molecules in order to identify predictive factors of clinical benefit from vismodegib.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Antoine Italiano, Institut Bergonie Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCI-2011-02564 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- CDR0000691728
- IB-CHONDROG
- CHONDROG
- 8408 (Other Identifier: CTEP)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mesenchymal Chondrosarcoma
-
Leiden University Medical CenterCompletedMyxoid Liposarcoma | Mesenchymal Chondrosarcoma | Dedifferentiated Chondrosarcoma | Conventional ChondrosarcomaSpain, Netherlands
-
Italian Sarcoma GroupPharmaMarRecruitingMesenchymal ChondrosarcomaItaly
-
Sarcoma Alliance for Research through CollaborationCompletedLiposarcoma | Osteogenic Sarcoma | Ewing/Ewing-like Sarcoma | Rhabdomyosarcoma | Mesenchymal ChondrosarcomaUnited States
-
Klinikum StuttgartKlinikum Kassel GmbH (COSS-Biobank)Not yet recruitingOsteosarcoma | High Grade Sarcoma | Recurrent Osteosarcoma | Bone Sarcoma | Undifferentiated Pleomorphic Sarcoma | Bone Tumor | Extraskeletal Osteosarcoma | Osseous Sarcoma | Parosteal Osteosarcoma | Osteoblastic Osteosarcoma | Chondroblastic Osteosarcoma | Fibroblastic Osteosarcoma | Conventional Osteosarcoma | Conventional... and other conditions
-
National Cancer Institute (NCI)Active, not recruitingDedifferentiated Chondrosarcoma | Central Chondrosarcoma, Grade 2 | Central Chondrosarcoma, Grade 3 | Metastatic Clear Cell Sarcoma of Soft Tissue | Metastatic Primary Central Chondrosarcoma | Unresectable Primary Central ChondrosarcomaUnited States, Canada
-
National Cancer Institute (NCI)SuspendedMetastatic Primary Central Chondrosarcoma | Unresectable Primary Central Chondrosarcoma | Locally Advanced Unresectable Primary Central ChondrosarcomaUnited States
-
National Research Center for Hematology, RussiaUnknownMesenchymal Stem Cell TransplantationRussian Federation
-
University of AarhusCompletedMesenchymal Stem Cells
-
Memorial Sloan Kettering Cancer CenterAgios Pharmaceuticals, Inc.RecruitingChondrosarcoma | IDH1 Gene Mutation | Chondrosarcoma, Grade 2 | Chondrosarcoma, Grade 3United States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States